CA2938019A1 - Retro-inverso analogs of spadin display increased antidepressant effects - Google Patents

Retro-inverso analogs of spadin display increased antidepressant effects Download PDF

Info

Publication number
CA2938019A1
CA2938019A1 CA2938019A CA2938019A CA2938019A1 CA 2938019 A1 CA2938019 A1 CA 2938019A1 CA 2938019 A CA2938019 A CA 2938019A CA 2938019 A CA2938019 A CA 2938019A CA 2938019 A1 CA2938019 A1 CA 2938019A1
Authority
CA
Canada
Prior art keywords
seq
analog
spadin
mixtures
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2938019A
Other languages
English (en)
French (fr)
Inventor
Georges Gaudriault
Catherine Heurteaux
Jean Mazella
Marc Borsotto
Hamid MOHA OU MAATI
Julie VEYSSIERE
Original Assignee
Centre National de la Recherche Scientifique CNRS
MedinCell SA
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, MedinCell SA, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2938019A1 publication Critical patent/CA2938019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2938019A 2014-01-27 2015-01-27 Retro-inverso analogs of spadin display increased antidepressant effects Abandoned CA2938019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931954P 2014-01-27 2014-01-27
US61/931,954 2014-01-27
PCT/IB2015/000338 WO2015110915A2 (en) 2014-01-27 2015-01-27 Retro-inverso analogs of spadin display increased antidepressant effects

Publications (1)

Publication Number Publication Date
CA2938019A1 true CA2938019A1 (en) 2015-07-30

Family

ID=53264690

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938019A Abandoned CA2938019A1 (en) 2014-01-27 2015-01-27 Retro-inverso analogs of spadin display increased antidepressant effects

Country Status (5)

Country Link
US (1) US10251937B2 (https=)
EP (1) EP3099313B1 (https=)
JP (2) JP6640725B2 (https=)
CA (1) CA2938019A1 (https=)
WO (1) WO2015110915A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865205B2 (en) 2015-11-16 2024-01-09 Medincell S.A. Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
KR102250582B1 (ko) * 2018-05-11 2021-05-12 고려대학교 산학협력단 별아교세포 특이적 수동전도도 억제약물의 스크리닝 시스템 및 이의 활용
FR3099932B1 (fr) 2019-08-13 2022-11-25 Univ Limoges Peptides dérivés de la sortiline
US20240294603A1 (en) * 2023-03-02 2024-09-05 Transdermal Biotechnology, Inc. Systems and methods for delivery of spadin for treatment of depression or other indications
US11980651B1 (en) * 2023-06-21 2024-05-14 Transdermal Biotechnology, Inc. Systems and methods for treatment of hearing using dihexa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
EP2077278A1 (fr) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
US20120322060A1 (en) 2011-04-13 2012-12-20 Centre National De Le Recherche Scientifique - Cnrs - Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods
EP2866837B1 (en) 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865205B2 (en) 2015-11-16 2024-01-09 Medincell S.A. Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US12558309B2 (en) 2015-11-16 2026-02-24 Medincell S.A. Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue

Also Published As

Publication number Publication date
JP2020023508A (ja) 2020-02-13
EP3099313A2 (en) 2016-12-07
US20170072013A1 (en) 2017-03-16
WO2015110915A2 (en) 2015-07-30
EP3099313B1 (en) 2021-04-21
US10251937B2 (en) 2019-04-09
WO2015110915A3 (en) 2015-11-26
JP6640725B2 (ja) 2020-02-05
JP2017505772A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
US10251937B2 (en) Retro-inverso analogs of spadin display increased antidepressant effects
Cui et al. Designer self-assemble peptides maximize the therapeutic benefits of neural stem cell transplantation for Alzheimer’s disease via enhancing neuron differentiation and paracrine action
ES2777652T3 (es) Modulación de la actividad de proneurotrofinas
US20100178277A1 (en) Methods and compositions for stimulating cells
JP5405295B2 (ja) 神経疾患の予防または治療のうち少なくともいずれかを行うための（ｓ）−ロスコビチンを含む医薬品
JP5174653B2 (ja) 末梢神経毒症状を処置するためのａｄｎｆポリペプチドの使用
KR102489620B1 (ko) 신경변성 장애
US20240065988A1 (en) Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
EP3393496A1 (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
CN112703008A (zh) 治疗癫痫、发作和cns疾病的经口抗炎肽
US11306059B2 (en) Drug-induced activation of the Reelin signaling system
US8309684B2 (en) Synthetic analogues of neural regeneration peptides
JP4433082B1 (ja) 神経新生促進剤
ES2935705T3 (es) Un ligando del receptor GABA A
ES2340708T3 (es) Tratamiento de esclerosis lateral amiotrofica con pirimetamina y analogos.
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
CN110869015B (zh) 用于治疗神经炎性紊乱的有机小分子
JP7825238B2 (ja) アミロイドペプチドバリアント
IL309754A (en) SCO-SPONDIN-derived polypeptides for enhancing synaptic transmission
CA3009506C (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
JP3361100B2 (ja) Ｃｃｋ受容体アンタゴニストとしてのインドール誘導体
HK40050388B (zh) 用於激活骨祖细胞中细胞信号传导的肽
MOISEIWITSCH et al. Embryonic Development

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191230

FZDE Discontinued

Effective date: 20220330